LifeTech Scientific Corporation (01302) said its loss attributable to shareholders for the six months ended 30 June 2014 widened to Rmb199 million from Rmb56.04 million for the same period in 2013.
Such loss was primarily due to the record of fair value loss of conversion option of the first tranche convertible notes issued on 30 January 2013 of about Rmb239.7 million. The fair value loss on convertible notes is a non-operating and non-cash flow item. Excluding the influence of this part, LifeTech Scientific would have recorded profit attributable to owners of about Rmb40.5 million, representing a high growth as compared to the corresponding period in 2013.
Its basic and diluted loss per share was Rmb39.8 cents.
The revenue was Rmb136 million, an increase of 24.8% from a year earlier.
No interim dividend will be distributed.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情
